These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16546547)

  • 21. The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy.
    Glatman-Freedman A
    Tuberculosis (Edinb); 2006; 86(3-4):191-7. PubMed ID: 16584923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction and immunogenicity of the DNA vaccine of Mycobacterium Tuberculosis dormancy antigen rv1733c.
    Zhang W; Jiang H; Bai YL; Kang J; Xu ZK; Wang LM
    Scand J Immunol; 2014 May; 79(5):292-8. PubMed ID: 24498941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis.
    You Q; Jiang C; Wu Y; Yu X; Chen Y; Zhang X; Wei W; Wang Y; Tang Z; Jiang D; Wu Y; Wang C; Meng X; Zhao X; Kong W
    Scand J Immunol; 2012 Jan; 75(1):77-84. PubMed ID: 21916923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool.
    Karp CL; Wilson CB; Stuart LM
    Immunol Rev; 2015 Mar; 264(1):363-81. PubMed ID: 25703572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity.
    Sable SB; Kalra M; Verma I; Khuller GK
    Clin Immunol; 2007 Mar; 122(3):239-51. PubMed ID: 17208519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen.
    Parra M; Cadieux N; Pickett T; Dheenadhayalan V; Brennan MJ
    Infect Immun; 2006 Jan; 74(1):786-9. PubMed ID: 16369041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simplified deoxypropionate acyl chains for Mycobacterium tuberculosis sulfoglycolipid analogues: chain length is essential for high antigenicity.
    Gau B; Lemétais A; Lepore M; Garcia-Alles LF; Bourdreux Y; Mori L; Gilleron M; De Libero G; Puzo G; Beau JM; Prandi J
    Chembiochem; 2013 Dec; 14(18):2413-7. PubMed ID: 24174158
    [No Abstract]   [Full Text] [Related]  

  • 28. New vaccines against tuberculosis.
    Mark Doherty T
    Trop Med Int Health; 2004 Jul; 9(7):818-26. PubMed ID: 15228493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
    Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
    Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein.
    Stukova MA; Sereinig S; Zabolotnyh NV; Ferko B; Kittel C; Romanova J; Vinogradova TI; Katinger H; Kiselev OI; Egorov A
    Tuberculosis (Edinb); 2006; 86(3-4):236-46. PubMed ID: 16677861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A study of the protective effect of the DNA vaccine encoding tubercle antigen 85B with MPT64 in mice challenged with Mycobacterium tuberculosis].
    Luo XD; Zhu DY; Chen Q; Jiang Y; Jiang S; Yang C
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Sep; 27(9):611-6. PubMed ID: 15498274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of vaccine research and development: tuberculosis.
    Girard MP; Fruth U; Kieny MP
    Vaccine; 2005 Dec; 23(50):5725-31. PubMed ID: 16153751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of T-cell location rekindled: implication for tuberculosis vaccination strategies.
    Xing Z
    Expert Rev Vaccines; 2009 Nov; 8(11):1465-8. PubMed ID: 19863237
    [No Abstract]   [Full Text] [Related]  

  • 35. One decade on.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2011 Aug; 11(8):579. PubMed ID: 21798456
    [No Abstract]   [Full Text] [Related]  

  • 36. Challenge of developing new tuberculosis vaccines to generate life-long protective immunity.
    Triccas JA; Nambiar JK
    Expert Rev Vaccines; 2009 Jul; 8(7):823-5. PubMed ID: 19538108
    [No Abstract]   [Full Text] [Related]  

  • 37. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.
    Geluk A; van den Eeden SJ; van Meijgaarden KE; Dijkman K; Franken KL; Ottenhoff TH
    Vaccine; 2012 Dec; 30(52):7513-21. PubMed ID: 23103299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in tuberculosis vaccine development.
    Baumann S; Nasser Eddine A; Kaufmann SH
    Curr Opin Immunol; 2006 Aug; 18(4):438-48. PubMed ID: 16777396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.
    Sambandamurthy VK; Derrick SC; Hsu T; Chen B; Larsen MH; Jalapathy KV; Chen M; Kim J; Porcelli SA; Chan J; Morris SL; Jacobs WR
    Vaccine; 2006 Sep; 24(37-39):6309-20. PubMed ID: 16860907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Learning from natural infection for rational tuberculosis vaccine design: from basic science to translational research.
    Kaufmann SH
    Hum Vaccin; 2010 Aug; 6(8):614-8. PubMed ID: 21228631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.